Sutro Biopharma stockholders elect four Class I directors, approve say-on-pay and auditor at 2022 annual meeting

SUTRO BIOPHARMA, INC.

Four Class I directors elected: Michael Dybbs, John G. Freund, Heidi Hunter, Jon Wigginton, each to serve three-year terms.
Ratification of Ernst & Young as independent auditor for FY2022 approved with 43,752,354 votes for, 11,569 against.
Advisory vote on named executive officer compensation (say-on-pay) approved with 40,921,442 for, 759,278 against.
Stockholders selected one-year frequency for future advisory votes on executive compensation; board adopts annual frequency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.